<DOC>
	<DOCNO>NCT00711516</DOCNO>
	<brief_summary>The primary objective study determine whether treatment armodafinil provide improvement prefrontal cortical activation patient OSAHS ( Obstructive Sleep Apnea/Hypopnea Syndrome ) residual sleepiness despite receive nCPAP therapy .</brief_summary>
	<brief_title>Study Evaluate Armodafinil Treatment Improving Prefrontal Cortical Activation Working Memory Performance</brief_title>
	<detailed_description />
	<mesh_term>Disorders Excessive Somnolence</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<criteria>Patient current diagnosis OSAHS complaint excessive sleepiness despite effective nCPAP therapy . Patient excessive sleepiness evidence mean sleep latency le 8 minute , determine MSLT . Patient ESS score 10 initial screen visit . Patient habitual sleep time begin early 2100 end later 0700 . Patient righthanded . Patients ambidextrous may eligible follow consultation medical monitor . Women childbearing potential must use medically accept method contraception must agree continue use method duration study 30 day participation study . Patient exhibit reasonable accuracy ( ≥80 % ) 2back work memory task training session second screening visit . The Patient : The patient current smoker prior history smoking ( define ≥1 packyear ) within 2 year prior screen visit . consumes caffeine include coffee , tea and/or caffeinecontaining beverage food average 400 mg caffeine per day ( approximately equivalent 4 cup coffee ) . NARTpredicted verbal IQ QIDSSR16 score within protocolspecific exclusionary range . clinically significant , uncontrolled medical psychiatric condition ( treat untreated ) . confirm probable diagnosis current sleep disorder OSAHS . use excluded prescription drug procedure prohibit allow drug within exclude timeframe . history alcohol , narcotic , drug abuse . positive UDS , without medical explanation , screen visit . clinically significant deviation normal physical examination . pregnant lactate woman . Any woman become pregnant study withdrawn study . past present seizure disorder , head trauma clinically significant , past neurosurgery . use investigational drug within 1 month screen visit . disorder may interfere drug absorption , distribution , metabolism , excretion ( include gastrointestinal surgery ) . know hypersensitivity armodafinil modafinil , component study drug tablet . history clinically significant cutaneous drug reaction , history clinically significant hypersensitivity reaction , include multiple allergy drug reaction . know human immunodeficiency virus ( HIV ) . clinical laboratory test value ( ) outside range ( ) specify Protocol , present clinically significant laboratory abnormality without prior write approval medical monitor . work night shift within 28 day baseline visit , work night shift doubleblind segment study . anticipates travel across 3 time zone time study . need use excluded medication identify protocol . unable complete neuroimaging study , performance task , selfrating scale , study assessment . contraindication fMRI scanning , ( implanted pacemaker/defibrillator , aneurysm clip , drug infusion device metallic foreign body ) . suspect unable tolerate fMRI scanning ( eg , claustrophobic ) and/or test paradigm . physical characteristic suggest image data unobtainable degrade .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>